Zevra Therapeutics Adds Infant Data to Its Niemann-Pick Drug MIPLYFFA
Zevra Therapeutics published positive Phase 2/3 pediatric substudy data for its Niemann-Pick type C therapy MIPLYFFA in infants under two, adding to the approved rare-disease drug's safety profile.
Zevra Therapeutics is quietly building the case for its rare-disease franchise, and new data in the youngest patients adds another supporting point.
Zevra is a commercial-stage biopharmaceutical company focused on rare diseases, with its lead product MIPLYFFA (arimoclomol) approved for Niemann-Pick disease type C, an ultra-rare, progressive neurological disorder. The company markets the therapy alongside a broader rare-disease portfolio.
On June 23 Zevra announced publication of positive results from a Phase 2/3 open-label pediatric substudy evaluating arimoclomol, added to miglustat, in five infants aged 12 to under 24 months. Over up to 36 months of treatment, the therapy was generally well tolerated with no new safety signals, and pharmacokinetics were consistent with older pediatric groups. The findings extend MIPLYFFA's profile into the youngest NPC patients, where options are scarce. In the pivotal Phase 3 trial, MIPLYFFA halted disease progression versus placebo over one year on the validated NPC Clinical Severity Scale.
The substudy enrolled only five children, so the results should be read as supportive rather than definitive, and commercial uptake remains the real driver of value.
This is market commentary, not investment advice — small-cap biotech stocks are highly speculative and you can lose your entire investment.
Get the next one first.
Small-cap biotech catalysts, filings and movers — free.
